Home/Pipeline/Generic Oncology Injectables Portfolio

Generic Oncology Injectables Portfolio

Various Cancers

ANDA Filed/ApprovedActive

Key Facts

Indication

Various Cancers

Phase

ANDA Filed/Approved

Status

Active

Company

Jubilant Pharmova

About Jubilant Pharmova

Jubilant Pharmova's mission is to become a leading global pharmaceutical company by delivering high-quality, affordable medicines through innovation and operational excellence. The company has achieved this through strategic vertical integration, building world-class manufacturing assets for complex APIs and sterile injectables, and establishing a strong global footprint. Its core strategy focuses on deepening capabilities in high-growth specialty segments like oncology and radiopharmaceuticals, while expanding its high-margin Contract Development and Manufacturing (CDMO) business to leverage global outsourcing trends.

View full company profile

Therapeutic Areas

Oncology Central Nervous System Allergy/Immunology Infectious Disease Cardiovascular Pain Management

Other Various Cancers Drugs

Drug	Company	Phase	Status
Oncology/Immuno-oncology Portfolio	MSD	Phase III/Commercial	Active
Bevacizumab Biosimilar	Dr. Reddy's Laboratories	Approved	Launched in UK
LADR Platform	LadRx	Preclinical	Research
Zip-Code Library for Oncology	Kodikaz Therapeutic Solutions	Pre-clinical	Active
Proprietary RLT Pipeline	Affibody	Not Specified (Preclinical-Phase 2)	Active
Preclinical ASO Portfolio	Isarna Therapeutics	Preclinical	Active
SPACE-GM Microenvironment Analysis	Enable Medicine	Research	Active
Oncology Program(s)	CIS Pharma	Pre-clinical	Active
Max Access Solutions (with The Max Foundation)	Tanner Pharma Group	N/A (Donation/Distribution Program)	Active
Oncology Immunotherapy Programs	Therapeutic Solutions International	Pre-clinical	Active
CPA Platform in Oncology	InnoSIGN	Development	Active
Oncology Services	Transcure Bioservices	Preclinical	Active